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by 
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ABSTRACT 
A plethora of research has investigated PTSD treatment outcomes among Veterans of 
foreign wars. However, research has suggested mixed treatment efficacy. Although investigations 
into factors that may help predict treatment outcomes are emerging, to date no study has 
evaluated treatment choice among Veteran populations. Previous treatment choice studies have 
yielded qualitative and quantitative information that can be useful in clinical decision-making. 
This study looks to build upon the treatment choice literature with combat Veterans to evaluate 
for underlining characteristics of cohorts that will help build upon existing knowledge. It has 
been suggested that treatment benefits Vietnam Era Veterans more than younger generations of 
Veterans. One of the suggested predictive factors of outcome is treatment choice; implying 
preference would differ between cohorts. This study did not lend evidence of different treatment 
preference between cohorts. Predictive factors were obtained for each treatment that could 
provide future research with data for hypothesis testing to improve the treatment selection 
process.  
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CHAPTER 1: INTRODUCTION 
Statement of Problem 
Department of Defense (DoD) released that after seven years of the War of Terror, 25% 
of combat Veterans from post-9/11 conflicts will meet criteria for posttraumatic stress disorder 
(PTSD; Department of Defense, 2010). In fact, five years after the invasion of Iraq, mental 
disorders were the second most frequent category of diagnosis at Veterans Affairs (VA) hospitals 
(Tanielian & Jaycox, 2008). The Veterans Health Administration (VHA) has received additional 
funds to treat this influx of combat Veterans seeking services. The VHA expanded programs that 
originated to treat Vietnam Veterans, with the inherent assumption that these programs would 
benefit all combat Veterans (Erbes, Curry, & Leskela, 2009). The VHA’s efforts to treat post-9/11 
Veterans have been called into question since differing rates of treatment effectiveness and 
attendance have been observed in Vietnam era and post-9/11 combat Veterans (Chard Schumm, 
Owens, & Cottingham, 2010).  
Background and Significance   
 PTSD is one of the primary difficulties faced by returning combat Veterans (Hoge et al., 
2004). PTSD is frequently described as a collection of hyper-responsive and inappropriate “fight 
or flight” responses (Yehluda, 2001). The term “fight or flight” first appeared in 1915 when 
Walter Cannon theorized that the physiological purpose of this response was an adaptive 
response to threat (Shiromani, Keane, & LeDoux, 2009). However, with PTSD the fight or flight 
mechanism that is adaptive during the trauma persists post-trauma and is associated with 
significant behavioral, cognitive, and social impairment (Hoge, 2010). 
Despite statistics illustrating that post-9/11 combat Veterans return from combat with 
significant psychological difficulties, post-9/11 combat Veterans are significantly less likely than 
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in Vietnam era Veterans to take advantage of available treatment options (Chard et al., 2010; 
Erbes, Curry, & Leskela, 2009). Although such factors as employment, family commitments, and 
symptom presentation are not supported as being associated with treatment use (Mott, Hundt, 
Sansgiry, Mignogna, & Cully, 2014; Erbes, Westermeyer, Engdahl, & Johnson, 2007), “Veteran-
era cohort” is highlighted as a predictive factor in who will attend treatment, with Vietnam era 
Veterans more likely to attend and benefit from mental health treatment than post-9/11 Veterans 
(Hundt et al., 2014; Erbes et al., 2009). 
Veteran opinion about the usefulness of different types of treatment is one area of inquiry 
that could lend an understanding to treatment utilization. Simply put, we need to know what 
kinds of treatments Veterans are willing to try. The literature is absent of treatment choice studies 
relevant to military populations. However, previous treatment choice studies relevant to the 
PTSD literature exist and focus on female sexual assault survivors (Cochran, Pruitt, Fukuda, 
Zoellner, & Feeny 2008; Zoellner, Feeny, Cochran, & Pruitt 2003; Zoellner, Feeny, & Bittinger, 
2009). These studies have yielded meaningful information that could provide evidence for 
treatment use in clinical settings. For example, an evaluation of a behavioral treatment designed 
to use extinction and habituation, prolonged exposure (PE) therapy, compared to the medication 
sertraline, a selective serotonin reuptake inhibitor produced primarily to treat depression, 
indicated that PE was preferred and perceived to be more effective in a sample of women who 
had no history of trauma (Cochran et al., 2008). However, when replicated among a sample of 
trauma-exposed women, the results suggested that a combination of PE and sertraline was 
preferred (Pruitt et al., 2012). In a qualitative evaluation comparing preference for either PE or 
sertraline, trauma-exposed participants cited practicality as their reasoning for endorsing 
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sertraline over PE alone (Zoellner et al., 2009). Thus, important differences may exist in 
treatment choice between non-clinical and clinical populations.  
Some previous studies have investigated what kinds of services combat Veterans might 
want to access after deployment, but not specific treatments for mental-health issues. For 
example, Sayer et al. (2010) found that combat Veterans reported Veterans were significantly less 
interested in treatment than in continuing education, obtaining employment, and receiving 
vocational training. However, Veterans’ lack of interest in treatment options does not reflect their 
clinical presentation, as many Veterans return from combat struggling with mental-health issues 
(Chard et al., 2010). Insight into factors that influence treatment choice could lead to increased 
treatment-seeking among combat Veterans, a population that presents with a great need for 
services (Cochran et al., 2008). 
Purpose  
 The primary purpose of this study is to evaluate potential underlying variables that 
impact treatment choice among Veterans in efforts to contribute meaningful information to 
formulate treatment planning. The current study will evaluate two cohorts of differing military 
generations: Vietnam era combat Veterans and post-9/11 combat Veterans. By obtaining data 
about treatment choice perceptions, perceptions of stigma, symptom endorsement, and 
personality, this exploratory study looks to find measures that could be used as predictive factors 
to treatment preference.   
Definition of Terms 
Cognitive Behavioral Therapy (CBT). CBT is an evidence-based practice relying on 
cognitive and behavioral principles. CBT focuses on the impact of maladaptive thinking and 
behaviors on mood. CBT is considered problem focused, with the primary objective of replacing 
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maladaptive patterns of thinking and behaving with adaptive ones. Although CBT originated as a 
unique manualized treatment, other therapies have been developed using CBT theory and 
modifications to treatment techniques. CBT is now considered an umbrella term for a large 
variety of treatments.  
Cognitive Processing Therapy (CPT). CPT is an adaptation of CBT theory designed to 
treat PTSD. CPT posits that PTSD occurs when the beliefs about trauma produce strong negative 
emotions that prevent accurate appraisals of the trauma. CPT focuses on cognitive restructuring 
of the event and exercises where the client writes narratives about the trauma then later (in 
session) evaluates the narratives for inaccurate appraisals.   
D-Cycloserine (DCS). Originally patented under the brand name Seromycin, DCS is an 
antibiotic medication developed for the treatment of tuberculosis. DCS is a partial agonist of 
NMDA glutamatergic receptors in the basolateral nucleus of the amygdala. Because of this 
action, studies have suggested that administration of this drug 30 to 60 min prior to a therapy 
session may enhance fear extinction when individuals are exposed to fear-eliciting stimuli.  
Department of Defense (DoD). The DoD is a department of the Federal United States 
government under the direction of the Executive Branch. The DoD’s function is to coordinate the 
involvement of any governmental operations that relate to national security or to the military.  
Eye Movement Desensitization and Reprocessing (EMDR). EMDR is a treatment that 
conceptualizes PTSD as symptoms that originate from disturbing memories. The belief is that 
these memories are stored in an isolated memory network that inhibits adequate processing. 
EMDR is similar in approach to CPT, however EMDR adds the bilateral sensory input, such as 
left to right eye movement following a clinician’s finger, while talking about the memory. The 
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theory is that this movement aids in adequate processing of the memory. The treatment typically 
takes 12-15 weekly sessions. 
Evidence Based Treatment (EBT). EBTs refer to treatments that integrate the best 
available research, clinical expertise, and client characteristics. Treatments obtain EBT status 
after receiving consistent replication of clinical trials in efficacy.    
Operation Enduring Freedom (OEF). OEF is the official name for the Global War on 
Terrorism by the United States. OEF is the ongoing conflict that began in Afghanistan on 
October 7, 2001. OEF refers to operations in Afghanistan, Philippines, Somalia, Georgia, 
Kyrgyzstan, Sahara, and the Caribbean of Central America.   
Operation Iraqi Freedom (OIF). OIF refers to the 2003 invasion of Iraq by the United 
States between March 19, 2003, and May 1, 2003. Some sources refer to OIF Veterans as any 
Veteran who served in combat operations after March 19, 2003. However, the operation name 
was changed after May 1 of that year. Instead of naming specific operations, much of the 
literature refers to combat Veterans of engagements in Iraq or Afghanistan after October 2001 
jointly as OIF/OEF Veterans.   
Post-9/11 Era Veteran. Refers to a Veteran who engaged in combat after the September 
11, 2001, attack on the World Trade Center in New York. These Veterans served in conflict after 
October 7, 2001 in Afghanistan, Iraq, Yemen, Pakistan, and currently campaigns in Syria and 
Iraq against the Islamic State of Iraq and Syria. This term is used interchangeably in other 
sources as Veterans of the Global War on Terrorism.  
Posttraumatic Stress Disorder (PTSD). PTSD is classified as a trauma and stress-
related disorder. PTSD occurs after an individual experiences at least one traumatic event that is 
followed by psychological and physical after the trauma such as avoidance of trauma reminders, 
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hyperarousal, and flashbacks of the traumatic event. These symptoms persist for over a month 
after trauma.    
Prolonged Exposure Therapy (PE). PE is an adaptation of CBT designed to treat 
PTSD. The PE conceptualization of PTSD is that symptoms are maintained through avoiding 
stimuli associated with the trauma, and this negative reinforcement strengthens the fear 
associations. Therefore, core components of PE are repeated exposures to stimuli that have been 
avoided since the onset of PTSD. During a typical PE exposure session, individuals are exposed 
to stimuli that elicit anxiety until the sympathetic nervous system is exhausted and physical 
symptoms of anxiety are no longer experienced. This occurs repeatedly until fear extinction is 
achieved.  
Selective Serotonin Reuptake Inhibitor (SSRI). SSRIs are a class of medication 
considered to be antidepressants and prescribed for the treatment of a variety of depressive and 
anxiety disorders. SSRIs limit the reabsorption of serotonin into the presynatpic cell, resulting in 
an increase of serotonin in the synaptic cleft available to bind to the postsynaptic receptors. 
SSRIs were developed on the theory that because decreased mood is a result of low serotonin 
levels, increasing serotonin levels has positive mood altering effects.  
Veterans Affairs (VA).  The VA is a government institution in the United States that 
serves, organizes, and disseminates benefits to American Veterans. The VA is split into three 
subdivisions: Veterans Health Administration, Veterans Benefits Administration, and the 
National Cemetery Administration.  
Veteran’s Health Administration (VHA). The VHA is the component of the VA that is 
charged with implementing health care to qualifying Veterans. The VHA is the largest integrated 
health care system in the world (VA, 2017).  
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Vietnam Era Veteran. Vietnam era is the term used in the United States to signify 
service during the time around the Vietnam War. To classify as a Vietnam era Veteran, military 
service must have occurred between February 28, 1961, and May 7, 1975. Conflicts during this 
time occurred in South Vietnam, North Vietnam, Cambodia, and Laos.  
Wilderness Experience Program (WEP). WEPs are organizations that conduct outdoor 
programs in wilderness environments for the purpose of therapy, rehabilitation, and education. 
For purposes of psychological treatment, WEPs do not have a formal structured therapeutic 
component. Instead, WEPs rely on building resilience and self-efficacy through natural 
consequences of the inherent challenges of living or traversing through wilderness environments.  
Wilderness Therapy (WT). WT is a WEP with a formal structured therapeutic 
component. No specific criteria are used to define WTs in the literature, and the term is used for 
a variety of settings and treatment orientations. The therapeutic component can be based on any 
theoretical orientation and ranges from “check-ins” to formal sessions such as tele-health 
communication including emails, phone calls, or video-chatting.  
 
 
 
  
  
15 
CHAPTER 2: LITERATURE REVIEW 
Five years after the invasion of Iraq by the United States military and 7 years after the 
War on Terror launched in Afghanistan, mental disorders were the second most frequent category 
of diagnosis at the Veterans Affairs (VA) hospitals (Tanielian & Jaycox, 2008). In 2009, the 
Department of Defense (DoD) estimated that 25% of combat Veterans – 125,000 individuals – 
were believed to possibly meet criteria for posttraumatic stress disorder (PTSD; DoD, 2010). 
Another report by VA officials showed that severe psychological distress among returning 
combat Veterans resulted in approximately 22 combat Veterans taking their own lives every day 
in 2012 (Kemp & Bossarte, 2013). However, a review of this report shows significant 
methodological errors and suggests this figure is likely a significant underestimate, with only 21 
states included and concerns over misclassification of the deceased as non-Veteran by 
documenting authorities.  
Currently, the first line of treatment for many combat Veterans is through the VA’s PTSD 
clinical teams and residential programs. The VA developed these programs primarily to treat 
PTSD among Vietnam-era Veterans and currently assumes its effectiveness in treating post-9/11 
combat Veterans (Erbes, Curry, & Leskela, 2009). The use of VA treatment protocols has been 
questioned because although comparison studies between pre- and post-9/11-era Veterans are 
limited, available data suggest different treatment effectiveness and attendance across cohorts 
(Chard et al., 2010). Post-9/11 combat Veterans are not benefitting as much as previous 
generations of Veterans.   
PTSD  
The primary mental health diagnosis among combat Veterans is PTSD (Hundt et al., 
2014). PTSD is characterized by the re-experiencing of a traumatic event accompanied by 
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symptoms of increased arousal, avoidance of trauma-related stimuli, and negative alterations in 
cognition and mood either beginning or worsening after the traumatic event [American 
Psychiatric Association (APA), 2013]. The APA first defined PTSD as an anxiety disorder in 
1980. The decision to include PTSD in the third edition of the Diagnostic and Statistical Manual 
(DSM-III; APA, 1980) was heavily influenced by the numerous Vietnam War Veterans who 
presented with psychological distress and disability both immediately following and for many 
years after their return from deployment (Neyland et al., 1998).  
PTSD is considered an adaptive response to fear learning (Hoge, 2010), and the most 
widely accepted model of fear learning is Pavlovian fear conditioning (Rosen & Schulkin, 1998). 
Conditioning of new fears involves pairing a neutral stimulus multiple times with a stimulus that 
naturally elicits a fear response. Because the stimulus that naturally elicits a fear response does 
not have to be taught, it is called the unconditioned stimulus (US). The fear response to a US is 
called an unconditioned response (UR). Once the neutral stimulus is paired repeatedly with the 
US, it will begin to elicit a fear response, even when the US is no longer present. The neutral 
stimulus is now a conditioned stimulus (CS), and the learned fear response is a conditioned 
response (CR). Laboratory examples have long shown that after continued pairings, the fear 
response is a learned response to the CS (Wolpe, 1982).  
Interestingly, individuals with PTSD can engage in behavioral avoidance and other 
symptoms of fear learning after a single pairing of the US and CS. The Rescorla-Wagner Model 
(Rescorla & Wagner, 1972) illustrates how organism appraisal and expectancy can impact the 
speed of learning. If the event is unexpected and the individual loses the perception of control 
over his/her life or self, the fear response is conditioned faster, often immediately, and can 
become chronic (Cantor, 2009). In fact, feeling as though the individual has lost control in 
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fearful situations has been shown to lead to PTSD symptoms even in the absence of a specific 
life-threatening event (Basolu, Livanou, & Crnobaric, 2007). Therefore, if an event was 
unexpected, and the individual felt powerless or appraised the event as life threatening, the 
association could be made after a single pairing of the CS and US. Support for this idea not only 
comes from clinical observation, but also from animal observations in laboratory settings (Foa, 
Zinbarg, and Rothbaum, 1992).   
Impact of PTSD 
 Physiological impact. PTSD has been described as an adaptive response to a severe 
stressor that has promoted survival (Hoge, 2010), and evolutionary explanations of PTSD 
support this hypothesis (Cantor, 2009). That is, learning rather quickly to avoid a life-threatening 
situation potentially promotes survival of the species. Initial beliefs of the physiological 
mechanisms of PTSD led clinicians to believe symptoms were merely over-exaggerated 
symptoms of anxiety (Yehuda, 2001). Because of this misunderstanding, treatment attempts were 
misguided, and some led to worsening of symptoms. One frequent iatrogenic effect occurred 
with heavy reliance on benzodiazepines (Raskind, 2009), a GABAA agonist used to treat anxiety 
that induces sedation and has a high addiction potential (Stahl, Grady, & Munter, 2005). New 
discoveries have recognized that PTSD is not just an over-exaggerated stress response but a 
condition with physiological markers that differ from an anxiety diagnosis. Differences in the 
clinical profile may be too poorly understood to consistently treat with prescription medications. 
For example the hormone cortisol is released as part of the stress response (Dickerson & 
Kemeny, 2004), but studies evaluating cortisol levels among PTSD patients show differences in 
response. Although cortisol levels in some patients were significantly elevated, levels in others 
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were significantly decreased. Meaning that although symptom presentation was consistent, 
physiological differences existed (Yehuda, 2001).  
 Cognitive impact. One of the common features of PTSD is the pervasive change in 
memory related to the trauma, with some aspects of memory enhanced and others diminished. 
For example, memories of the trauma might occur repeatedly and often manifest as re-
experiencing symptoms, such as unwanted, distressing, and poorly controlled recollections of the 
traumatic event (Verfaellie & Vasterling, 2009). Alternatively, another diagnostic symptom of 
PTSD is the inability to recall important aspects of the traumatic event (APA, 2013).  
In addition to memory related to the trauma, general autobiographical memory and ability 
to encode and retrieve new information may also be observed in those with PTSD. Using the 
Autobiographical Memory Test (AMT), researchers found that although Vietnam-era Veterans 
with PTSD could recall general information about autobiographical memories encoded after the 
trauma but had trouble with recalling specific information. In contrast, trauma survivors without 
a PTSD diagnosis were better able to recall specific information about autobiographical 
information (McNally, Lasko, Macklin & Pitman, 1995). The AMT requires verbal cues, but 
similar results in a civilian population with PTSD were observed when visual cues were used 
(Schonfeld & Ehlers, 2006). This provides evidence that memory deficits are present across 
different types of perceptual cues. Moreover, when evaluating memory content, positive 
memories are recalled with significantly less detail than negative memories in those with a PTSD 
diagnosis (McNally et al., 1995).  
Difficulties in memory can have significant treatment implications. An individual’s sense 
of self is strongly tied to defining autobiographical memories (Beck, 2011). When asked to recall 
self-defining memories, individuals with PTSD reported more trauma-related memories and 
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memories of negative emotional valence than positive or neutral memories (Sutherland & 
Bryant, 2005). This prevalence in recall of negative memories can skew perceptions of self in 
many facets of functioning that additionally complicate treatment and require clinical attention 
(Beck, 2011).  
Although some suggest that memory impairment is a predictive factor for who will 
develop PTSD after trauma, evidence suggests that the relationship may actually be the opposite. 
That is, memory impairment likely occurs as a result of trauma. In Veterans assessed before and 
after one deployment to Iraq, declines in verbal and visuospatial memory were observed only in 
those with psychological symptoms of trauma after deployment (Vasterling et al., 2006). 
Observations such as this have led some to speculate that symptoms of PTSD occur only if the 
traumatic event first leads to the physiological response that then may impair memory (Rubin, 
Berntsen, & Bohni, 2008).  
Findings regarding the physiological causes of memory impairments among those with 
PTSD have been fairly consistent (Verfaellie & Vasterling, 2009). One explanation is that the 
hippocampus may experience neuronal degeneration due to the neurotoxicity of significantly 
elevated glucocorticoid responsiveness (Yehuda, 2001). In support of this explanation, Vietnam 
Veterans with PTSD showed a significant 8% reduction in hippocampal volume compared to 
Vietnam Veterans without a PTSD diagnosis (Bremmer et al., 1995). This reduction in volume 
was associated with a 40% deficit on scores of verbal memory tasks as measured by the Wechsler 
Memory Scale.  
If left untreated, memory difficulties associated with PTSD are seen across the lifespan, 
with a steeper decline in memory formation and recall observed in elderly patients with PTSD 
and compared to their cohort without a PTSD diagnosis (Yehuda et al., 2006), thus potentially 
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making activities of daily living more difficult as individuals with PTSD age. Memory 
impairments caused by PTSD have consequences beyond the cognitive domain. Impaired 
memory has been shown to lead to physical health consequences, with data suggesting that those 
with a diagnosis of PTSD and heart disease were 80% more likely to forget taking necessary 
medications for heart disease than the control group with heart disease but not PTSD (Zen et al., 
2012). However, memory impairment after trauma is not necessarily permanent. Evidence 
suggests that after completing cognitive behavioral therapy (CBT) for PTSD, a decrease in PTSD 
symptoms was associated with improved memory retrieval, particularly in response to positive 
cues (Sutherland & Bryant, 2007).  
 Social impact. Interpersonal problems are among the most significant concerns of 
returning combat Veterans (Milliken, Auchterlonie, & Hoge, 2007; Dekel & Monson, 2010). 
Symptoms of PTSD such as hyper-vigilance, increased sensitivity to perceived threats, and 
behavioral avoidance frequently erode interpersonal resources needed to maintain social support 
(Brancu et al., 2014). For example, one study showed that over half (57%) of combat Veterans 
reported difficulties controlling their anger (Sayer et al., 2010). In addition, lack of social support 
has long been established as the greatest predictive factor in developing and maintaining PTSD 
after a traumatic event (Brewin, Andres, & Valentine, 2000). 
Treatment Effectiveness Among Veterans  
Shortly after the wars in Iraq and Afghanistan began, PTSD was reported to be the most 
present concern faced by returning combat Veterans (Hoge et al., 2004). This concern was 
previously shown among Vietnam Veterans as well (Zatzick et al., 1997). Treatments that show 
general efficacy within civilian populations only show limited efficacy within Veteran 
populations (Schnurr et al., 2003) Since this discrepancy was first reported, several possible 
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explanations have been postulated. One explanation involves combat Veterans waiting to seek 
treatment until symptoms become severe (Bradley et al., 2005). Greater symptom expression 
leads to increased treatment difficulty and typically requires more intensive treatment. Another 
possible influence on treatment outcomes is the tendency for combat Veterans to limit social 
interactions, including treatment, in fear of displaying symptoms to others. When limiting social 
interactions, it is hypothesized that the avoidance behaviors diminish opportunities to habituate 
to fear-provoking stimuli and significantly decrease social support, a high frequency of both are 
necessary for the natural stress recovery to occur. Finally, it is suggested that compensation 
through disability claims provide reinforcement to continually display symptoms. In this view, 
Veterans are not as motivated to recover from symptoms as civilians because of secondary gains. 
Some support does exist for this claim. Cully and colleagues (2008) found that Veterans with at 
least a 50% service connection who receive increased access and benefits are less likely to attend 
treatment.  
Treatment of post-9/11 Veterans does not appear to be as attractive or efficacious as with 
Vietnam Veterans. Data collected at a number of VA hospitals and supported by clinician 
consensus based on clinical observation suggest that post-9/11 Veterans who actively seek 
treatment are less likely to attend treatment regularly and more likely to completely abandon 
treatment (Erbes et al., 2009). Symptom presentation was suggested as a casual factor, as 
depression and treatment attendance are negatively correlated among post-9/11 Veterans (Erbes, 
et al., 2007). However, comparisons between post-9/11 Veterans to Vietnam Veterans showed 
that cohort was a stronger predictive factor than symptoms (Erbes et al., 2009), with Vietnam 
Veterans more likely to seek out and attend treatment. Another study showed that patient age was 
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the only significant predictive factor (Hundt et al., 2014). Further evaluation of the mediators 
associated with age is needed to understand this relationship. 
Treatment is more likely to be prematurely terminated by post-9/11 Veterans and then 
reinitiated under a crisis situation requiring more intensive treatment (Mott, Hundt, Sansgiry, 
Mignogna, & Cully, 2014). Even with a formal diagnosis of PTSD, one study showed that only 
35% of post-9/11 Veterans sought treatment within one year (Culley et al., 2008). Caregivers’ 
reports also lend evidence that symptom severity is not a satisfactory explanation for differential 
treatment seeking behaviors between the cohorts. Of respondents, 64% of caregivers who cared 
for a post-9/11 combat Veteran reported a mental health diagnosis as opposed to 36% of pre-9/11 
combat Veterans. Moreover, 75% of post-9/11 caregivers reported they had to provide assistance 
to their Veteran in coping with stressful situations, as opposed to only 46% among pre-9/11 
Veteran caregivers (Ramchand et al., 2014).   
Evaluating the multitude of factors that could be influencing treatment seeking behaviors 
and subsequent adherence has yielded several possibilities, although it is unlikely that a single 
cause has led to this discrepancy. One factor to consider is that the number post-9/11 Veterans 
wounded in combat is significantly higher than previous American wars (Carlock, 2007). 
Furthermore, Vietnam Veterans typically served one year-long tour. In contrast, post-9/11 
Veterans typically serve multiple deployments and many have been injured, recovered, and 
redeployed (Hafemeister & Stockey, 2010). This pattern of deployment could be a significant 
factor because frequency and intensity of combat experiences are among the strongest predictors 
of future PTSD symptoms (Department of Veterans Affairs, 2010).    
Survival rates of Veterans wounded in action are another suggested factor for increased 
PTSD provenance rates in recent combats. Early into the wars in Iraq and Afghanistan, the 
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survival rate of wounded individuals reached approximately 90% due to technological advances 
in body armor, improved understanding and training of field combat medicine, and increased 
efficiency in evacuating the wounded (Gawande, 2004). The wounded-to-killed ratio of the 
Vietnam War was 2.6 to 1, whereas the wounded-to-killed ratio of Afghan and Iraqi wars was 15 
to 1 (Hafemeister & Stockey, 2010). Although this increase in combat survival is clearly a 
positive change, injuries significantly alter quality of life for combat Veterans after 
injury/trauma. As of 2006, more than half of combat-wounded Americans suffered brain damage 
that resulted in permanent changes in their cognition, mood, and behavior, thus severely 
impacting their ability to successfully reintegrate to civilian life (Friedman, 2006).  
Epidemiological studies suggest that Vietnam-era and post-9/11 Veterans present to 
treatment with different concerns that could influence treatment efficacy. For example, Vietnam 
Veterans are more likely to report substance use disorders. On the other hand, post-9/11 Veterans 
are more likely to report difficulties with anger management and violent behavior than Vietnam 
Veterans. Despite injuries suffered during combat, post-9/11 Veterans are less likely to file a VA 
disability claim citing a PTSD diagnosis (Fontana & Rosenheck, 2008). Other characteristics are 
suggested based on clinical observation, such as reliance on technology, gender, and marital 
status. However, additional quantification is necessary to validate these claims and understand 
their impact on diagnosis and treatment. Despite low treatment attendance, data supports that 
post-9/11 combat Veterans are concerned with reintegration and interested in resources to assist 
in the transition. VA researchers found that 96% of respondents were interested in services that 
focused on reintegration (Sayer et al., 2010).  
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VA Treatments 
 In 2010, the Department of Veteran Affairs released Management of Post-Traumatic 
Stress to serve as a clinical guideline for treating PTSD (DVA, 2010). Approximately 50 
clinicians from the VA and DoD developed the guidelines with the goal of evaluating evidence 
for treatments that emerged since the previous guidelines in 2004. The group unanimously 
supported the use of treatments developed from a CBT framework. However, as of 2009, none of 
these treatments were designed around theory or literature specifically on Veteran populations 
(Erbes et al., 2009).  
Cognitive processing therapy. Cognitive Processing Therapy (CPT) focuses on 
challenging and modifying maladaptive beliefs that are considered stuck points in recovery 
(Resnick, Monson, & Chard, 2007). The addition of writing trauma narratives serves as an 
exposure component of the treatment (Resnick, Monson, & Chard, 2007). The manual allows for 
flexibility regarding setting as CPT can be practiced in an individual or group setting.  
Research evaluating the efficacy of CPT in Veteran populations has demonstrated 
symptom reduction when compared to waitlist controls (Monson et al., 2006). Unfortunately, no 
studies have dismantled the components of CPT to assess efficacy for this population. Only one 
treatment dismantling study has been conducted at the time of this manuscript and it was 
conducted using a population of female sexual assault survivors (Resick et al., 2008). 
Participants were assigned to one of three groups receiving either CPT, the cognitive therapy 
component alone, or the written exposure alone. The full CPT condition and the cognitive-only 
condition showed no significant difference, but the narrative component was significantly less 
effective in reducing PTSD symptoms immediately after treatment. However, the within-
participant design of this study yielded a decrease in PTSD symptoms across all three groups. All 
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groups still showed mild PTSD symptom reduction at the 6-month follow-up, but there were 
statistically  nodifferences among groups . This finding lent evidence that the combination of 
treatment components was as effective as the individual parts in isolation at follow-up.  
In the initial study using CPT with a Veteran population, 50 Veterans, all with a diagnosis 
of PTSD, completed the full 12-session treatment prescribed in the treatment manual. After 
treatment, 40% no longer met criteria for PTSD, and 50% had a significant change in their 
symptoms. Although re-experiencing and emotional-numbing symptoms did significantly 
improve, behavioral avoidance and hyperarousal symptoms did not significantly differ from pre- 
to post-treatment (Monson et al., 2006). Additionally, in a study evaluating effectiveness in 
OIF/OEF and Vietnam Veterans, CPT was shown to be effective for both cohorts. However, the 
OIF/OEF cohort had a significantly lower session attendance rate than the Vietnam cohort 
(Chard et al., 2010). In other words, OIF/OEF Veterans were less likely to attend treatment 
sessions than their counterparts.  
Since the VA began to make efforts to disseminate empirically based treatments (EBTs) 
throughout the VAHs, studies have been conducted on the effectiveness of this work. Alvarez and 
colleagues (2011) used a retrospective-cohort design to compare CPT with a previously assessed  
treated cohort considered treatment as usual. Their results indicated significant symptom 
improvement in the CPT cohort over the treatment-as-usual cohort in symptoms of PTSD, 
depression, and improved quality of life (Weathers et al., 2013).  
Prolonged exposure. Among treatments for PTSD, exposure-based treatments have been 
studied more than other treatments (VA, 2010). Exposure treatments are designed to modify 
associations between a feared stimulus (the CS) and avoidance behaviors that negatively 
reinforce the fear. Exposure therapies involve repeated exposure to feared stimuli while 
  
26 
practicing response prevention. By disassociating the CS and CR, the sympathetic nervous 
system responses lessen over time, which leads to behavioral extinction (Abramowtiz, Deacon, 
& Whiteside, 2012). Among differing exposure-based treatment options, Prolonged Exposure 
(PE) is recommended for treatment by the VA. PE combines imaginal exposure and in-vivo 
exposure of the traumatic event and associated stimuli (VA, 2010). In addition to the exposure 
component, cognitive restructuring is a suggested, but not a required component, to strengthen 
the new associations learned during the exposure (Eftekhari, Stines, & Zoellner, 2006). Imaginal 
exposure to the event occurs through thinking about and vocalizing the experience in detail 
(including physical and emotional descriptions). In-vivo exposure occurs through confronting the 
feared stimuli in a hierarchical fashion beginning with the stimulus that is perceived to be the 
easiest to confront.  
Dismantling exposure-based therapies has led to mixed results in the literature on 
component efficacy, particularly in the use of cognitive restructuring. For instance, a study of 
civilian trauma showed a less robust decrease in symptoms of PTSD and depression if the 
cognitive component was omitted (Bryant et al., 2008). However, a meta-analysis concluded that 
when the focus of treatment was on decreasing behavioral avoidance only, the additional 
cognitive component did not contribute to efficacy. The cognitive component is theorized to be 
ineffective because the experience of challenging and restructuring thoughts is done without 
clinician directives (Wolitzky-Taylor, Horowitz, Powers, & Telch, 2008). When compared to 
present-centered therapy, female Veterans showed a greater decrease of symptoms with PE 
(Schnurr et al., 2007), although a limitation to the study is small sample size (n = 10). Taken 
together, research studies with PE provide evidence of PE effectiveness across generations and 
gender (Rauch et al. 2009). Nevertheless, more Veteran-specific studies are needed on PE and 
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other exposure-based treatments to obtain a deeper understanding of the therapeutic mechanisms 
(VA, 2010).  
 Eye movement desensitization and reprocessing. Eye Movement Desensitization and 
Reprocessing (EMDR) includes imaginal exposure and cognitive therapy while simultaneously 
performing eye movements during the exposure (Shapiro, 1989). Although the effective 
mechanism of EMDR is reported to be the bilateral movement of the eyes (Shapiro, 1989), two 
meta-analyses found no support for the eye-movement component of EMDR (Devilly, 2002; 
Davidson & Parker, 2001). The VA (2010) suggests that aside from the eye movements, other 
components of EMDR are the same as cognitive and exposure-based therapies. Spates and 
colleagues (2009) reported that without further evidence, the eye movements during sessions are 
unnecessary. However, despite the unproductive eye movements, evidence suggests EMDR is as 
effective as trauma-focused CBT (DoD, 2010).   
Selective serotonin reuptake inhibitors. When PTSD was first added to the DSM in 
1980, research in pharmacological treatment was nonexistent, and prescribers had to rely on 
symptom overlap with other disorders when making medication decisions. The result was 
frequent prescriptions of antidepressants, anxiolytics, and sedative hypnotic medications used 
“off label” with very little consistent efficacy observed (Raskin, 2009). Since then, selective 
serotonin reuptake inhibitors (SSRIs) have been used as a first-line pharmacological treatment 
for PTSD, and a meta-analysis supports their use (Stein, Isper, & Seedat, 2006), with treatment 
guidelines suggesting that SSRIs be taken for 12-24 months (Bandelow et al., 2014). However, 
Stein and colleagues (2006) reported that studies typically exclude combat Veterans from their 
analysis, focusing instead on civilian trauma. In fact, they suggested that research should be 
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conducted on the possibility that combat exposure is a predictive factor for SSRI non-
responsiveness in treating PTSD.  
This use of SSRIs in treating PTSD is considered a “significant benefit” and “strongly 
recommended” (VA, 2010) is largely based on randomized control trials with civilian 
populations and rarely target Veteran specific populations. Unfortunately, when randomized 
control trials evaluate pharmacological treatments specifically for Veterans, the results are 
contradictory to what is observed in comparable civilian populations regarding symptoms 
presentation (Friedman, 2006). In fact, the literature has provided evidence since the early 1990s 
that combat Veterans may not respond to SSRIs in a similar fashion as survivors of civilian 
trauma (van der Kolk et al., 1994). In fact, a VA study conducted between fluoxetine (an SSRI) 
and placebo showed that twice as many participants in the placebo group had a significant 
decrease in PTSD symptoms (Hertzberg et al., 2000).  
Barriers to Treatment  
Individual barriers. When evaluating barriers to treatment, factors unique to the 
individual may inhibit treatment-seeking behaviors. For example, a frequently endorsed barrier 
to care among combat Veterans is practicality in attending weekly appointments (Stecker et al., 
2007). The relative high frequency of appointments when compared to other health-care 
professional appointment SPREADS is not a problem unique to Veterans. In a sample of civilian 
women with PTSD who chose medication over psychotherapy, ability to attend therapy regularly 
was the most frequently reported concern as well (Cochran et al., 2008). Frequently the barriers 
to treatment are perceptual rather than realistic, with a positive correlation observed between 
PTSD symptoms and perceived barriers to care (Ouimette et al., 2011). That is, those with more 
severe symptoms are more likely to report that they cannot attend therapy regularly.  
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Geographical distance from treatment opportunities may be a casual factor in treatment 
underutilization in rural populations (McCarthy & Blow, 2004). Approximately one third of 
OIF/OEF Veterans return to the rural south, where mental-health services are less readily 
available (Kirchner et al., 2011). Indeed, the VHA has worked diligently to create rural satellite 
clinics and tele-health equipment for use by Veterans. Veterans living in rural areas with a mental 
health diagnosis are less likely to report receiving treatment, even more so when specialty care is 
required (Wang et al., 2005). Studies have been conducted showing that distance to a VA hospital 
is significantly related to fewer psychotherapy services (Cully et al., 2008) regardless of 
symptom presentation or demographics (Culley et al., 2010).  
A treatment barrier specific to younger combat Veterans is the perception of fit between 
themselves and the treatment setting (Ouimetter et al., 2011). When senior citizens are dual 
enrolled in Medicare and VA benefits, 94% of seniors use the VA system for their mental health 
and inpatient care (Petersen et al., 2010). This has led the average age of patients at the VA to be 
approximately 70 years old (Ouimetter et al., 2011). This leaves younger Veterans feeling 
uncomfortable as they feel the VHA’s purpose is to serve primarily older Veterans.   
Institutional barriers. The institution providing care may be a significant source of 
imposed barriers. For example, one commonly cited explanation for low treatment-seeking 
behavior is long wait times (Tanielian & Jaycox, 2008; Hoge et al., 2004). Strategies used to 
disseminate information are possible barriers to treatment if execution is poor or misguided. In 
an effort to make sure that combat Veterans know about available treatment services, the DoD 
may also have unintentionally served as an institutional barrier. The timing of education about 
services typically occurs shortly after a deployment, and as one Veteran reported, this may not be 
the best time.  
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When we came back from our deployment, we had to go through all these little classes,  
and some of these were mental health classes. Without a doubt, we knew that everybody  
was there to help us. The last thing on our mind was wanting that help. We wanted to go  
home (Stecker et al., 2007; pp. 1359).  
Although education about treatment services may appear to be best presented immediately after 
returning from deployment, Stecker and colleagues (2007) suggest that Veterans are not mentally 
prepared to retain such information and are more concerned with returning home. By having 
soldiers sit through these presentations immediately after returning home, the DoD may 
inadvertently be linking treatment with negative feelings.  
The clinicians themselves, through misunderstandings about treatment, can become 
barrier to effective treatment. One reason might be that clinicians exclude clients from treatments 
because the clinician has seen similar individuals excluded from randomized control trials of a 
treatment (Ronconi et al., 2014). For example, exposure-based treatments are largely excluded 
from clinical consideration due to concerns of inducing anxiety with other comorbid conditions 
(Zoellner et al., 2009). Until recently, there was no comprehensive review of inclusion and 
exclusion criteria used in randomized clinical trials that corresponded to clinical practice. 
However, evidence suggests that exclusion criteria used in clinical trials for participant selection 
should not be given strong consideration in clinical practice (Ronconi et al., 2014).   
Few VA psychotherapists appear to choose EBTs as an initial approach in treatment of 
PTSD (Rosen et al., 2004 Shiner et al., 2013), despite the massive dissemination efforts 
educating clincians and promoting benefits of EBTs (Zayfert et al., 2005; Shiner et al., 2013). 
Some have suggested patient preference for alternative treatment as a barrier to the delivery of 
EBTs for PTSD (Zoellner et al., 2009). Others have suggested a lack of clinical training in EBTs. 
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Training and opportunity do not appear to factors as many clinicians tend not to choose EBT for 
their patients despite receiving adequate training (Becker, Zayfert & Anderson, 2004). This 
suggests other unknown factors are playing a role in treatment choice by clinicians. Clinician 
choice of treatment options is an understudied area of research (Ronconi et al., 2014). One 
explanation may simply be clinician misunderstanding of PTSD. Although treatments that 
promote discussion and narratives of the trauma may be effective to some (Monsoon et al., 
2006), these treatments may be ineffective for others. Rauch et al. (1996) used positron emission 
tomography (PET) scans to show decreased activity in Broca’s area (the part of the brain 
responsible for speech) during the reading of trauma narratives, suggesting that talking through 
trauma may not be possible for some Veterans. 
Instead of acknowledging limitations to clinician-preferred treatments, some treatment 
theorists give suggestions as to how to work through “resistance.” Foa, Keane, and Friedman 
(2000) gave several suggestions, including hypnosis and medication, to work with “resistant” 
patients. Rather than attempt to identify ideal populations or conditions that respond better to 
specific treatments, they assumed the position that the patient was intentionally resistant to 
treatment. Relying on a lack of contrary evidence, they supported their position by stating that 
there was no evidence that treatments they outlined (i.e., cognitive therapy, prolonged exposure) 
were less effective in specific populations.  
 Societal barriers. Frequently one of the barriers many Veterans face in seeking treatment 
is the concern that others will view them differently if they know the Veteran is in treatment. 
Despite the fact that in one study OIF/OEF Veterans did not strongly endorse negative 
stereotypes associated with mental illness (Vogt, Fox, & DiLeone, 2014), in a recent analysis, 
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post-9/11 combat Veterans reported that workplace stigma was a major concern. Further, their 
concerns about career advancement served as a significant barrier.  
 Treatment-seeking behavior among combat Veterans may be impacted from stigma-
related beliefs. One study found that more than over 75% of post-9/11 combat Veterans 
diagnosed with PTSD, depression, of generalized anxiety disorder recognized their diagnosis and 
consequences. However, only 40% reported interest in receiving treatment (Brown et al., 2011). 
Perceptions of mental-health treatment among military leadership may play a significant role in 
treatment seeking. Evidence has shown that enlisted members of the military are likely to have 
the same views of mental health stigma as their superior, regardless if that view is positive or 
negative (Clark-Hitt, Smith, & Brokerick, 2011). Moreover, when enlisted service members were 
asked about their willingness to refer themselves and a subordinate to mental-health treatment, 
66% were willing to refer both themselves and others, and only 7% were not willing to refer 
themselves or others. No respondents were willing to refer themselves and not their subordinates 
(Johnston, Webb-Murphy, Raducha, & Abou, 2011).  
Distance is frequently proposed as being a barrier for rural individuals. However, a 
stringent evaluation of this claim suggests that societal influence is more of a barrier than 
distance (Kirchner et al., 2011). The valuation of self-reliance and independence is prevalent in 
rural culture. This combination of values, though adaptive in many situations, is believed to 
impede treatment-seeking behavior (Hauenstein et al., 2007).  
Cultural differences may significantly lead to comfort in clinical settings as well. As one 
combat Veteran stated: 
In going into a clinical environment, where you are going to talk about things that hurt 
your heart and that cause you great grief and distress, not only do you not know the 
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counselor that you are going to talk to, but you are walking into a sterile environment that 
is foreign to you (Stecker et al., 2007 pp. 1352).  
PTSD Treatments Revisited: Beyond the VA 
In response to barriers of treatment-seeking behavior, there has been a call for novel 
treatment options that may be better suited and more appealing to combat Veterans (Vogt et al., 
2014). The following section will cover select novel treatments currently for efficacy among 
Veteran populations.  
Wilderness experience programs. Wilderness Experience Programs (WEPs) are defined 
as “organizations that conduct outdoor programs in the wilderness or comparable lands for 
purposes of personal growth, therapy, rehabilitation, education, or leadership/organization 
development” (Friese, Hendee, & Kinziger, 1998, p. 40). The idea of using wilderness 
environments as a means to improve psychological health is not new (Schuster, 2003). Recently, 
researchers and clinicians increased their interest in WEPs to treat combat Veterans to provide a 
more comfortable treatment environment (Cassick & Smith, 2014). WEPs do not offer formal 
treatment protocols. Instead they operate through an experiential-learning paradigm and give 
individuals time to process and reflect on relevant events (Gelkopf, Hasson-Ohayon, Bikman, & 
Kravetz, 2013). 
Research into WEPs typically includes qualitative interviews or evaluating journals 
participants maintain during their experience. One example is a nine-day climb of Mt. 
Kilimanjaro, after which Veterans endorsed an increase in self-determination, active coping 
skills, and social support (Burke & Utley, 2013). As another example, during a four-day kayak 
trip, Veterans reported a decrease in arousal and an increase in positive mood (Dustin, Briker, 
Arave, Wall, & Wendt, 2011). As a slightly less compelling example, Veterans who took part in a 
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five-day adventure course did not show a decrease in symptoms, but they did evaluate the 
program positively and reported learning strategies to better cope with negative emotions (Hyer 
et al., 1996). Most studies include reports from short-term programs, usually less than two 
weeks, though more intensive programs exist. Veterans who engaged in a six-month hike through 
the Appalachian Trail reported an increase in social reconnection, life-improving change, and 
psychological healing. They indicated that the main contributing factor to their improvement was 
the time away from societal stressors that allowed for this process (Dietrich, Joye, & Garcia, 
2015).   
Wilderness therapy. WEPs are often designed so that participants experience natural 
consequences through guided learning (Gelkopf et al., 2013). Adding to this model, Wilderness 
Therapy (WT) combines the use of natural lands with a structured and more traditional treatment 
approach (Russell, 2001). A search did not yield studies investigating WT programs for combat 
Veterans, but such programs do exist. CBT-based WTs are emerging into the treatment literature, 
with evidence supporting increased benefit over traditional CBT treatment for adult populations 
with depression (Kim, Lim, Chung, & Woo, 2009), overweight adolescents (Jelalian et al., 2006), 
and elderly clients with hypertension (Sung et al., 2012).  
D-Cycloserine with exposure therapy. Studies have suggested that N-methyl-D-
aspartate (NMDA) glutamatergic receptor activity in the amygdala precedes fear learning and 
extinction (Norberg, Krystal, & Tolin, 2008). The partial NMDA agonist, D-Cycloserine (DCS) 
has been shown in animal models to enhance fear extinction due to increased NMDA receptor 
activity (Walker, Ressler, Lu, & Davis, 2002). DCS was originally developed as an antibiotic to 
treat tuberculosis (Hardman & Limbird, 2001). However, since the discovery that fear-extinction 
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was accelerated with DCS in animal models, interest in the potential use as a PTSD treatment 
has emerged.  
Working from the theory that DCS coupled with PE would increase treatment gains, de 
Kleine and colleagues (2012) found that 64% of their civilian sample showed significant clinical 
improvement as compared to the 38% of those in the PE plus placebo condition. However, 
within a small Veteran sample (12 per condition) that also received PE and DCS, no benefit was 
observed (Litz et al., 2012). The civilian population that showed benefit from administration also 
was administered DCS 60 minutes prior to treatment, whereas the military sample was 
administered DCS 30 minutes prior to session (both were administered 50 mg). DCS, originally 
developed as quick acting treatment, has a half-life of 10 hours, with peak serum levels after 4 
hours (Hardman & Hardman, 2001). Interestingly, one study was conducted on Persian combat 
Veterans who were administered DCS without any form of adjunctive treatment. The rational 
was that soldiers would learn from real-world and informal exposures, and additional treatment 
may not be necessary. Although small, a significant difference in self-report endorsement of 
avoidance behaviors was observed when compared to the placebo condition (Attari, Rajabi, & 
Maracy, 2014). DCS has shown promise in aiding fear extinction in disorders for which a 
sympathetic nervous response is a hallmark feature, such as specific phobia. However, more 
research is required for PTSD (Hoffmann, Wu, Boettcher, 2013; Norberg, Krystal, & Tolin, 
2008).  
SSRI with psychotherapy. Guidelines for the treatment of PTSD often refer to SSRIs as 
a first-line treatment (VA, 2010). However, others suggest the use of SSRIs as a second-line 
treatment in tandem with ongoing psychotherapy (Marshall & Cloitre, 2000). Although reporting 
assessments of a small sample (n = 10), one study found that the combination of SSRIs and CBT 
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led to significant improvements among Cambodian refugees (Otto et al., 2003). Another study 
suggested similar results in a larger sample of American civilians diagnosed with PTSD 
(Rothbaum et al., 2006). Unfortunately, these findings failed to replicate in other studies, with 
SSRIs showing no advantage over placebo when used in conjunction with PE (Simon et al., 
2008). Arguing that previous studies only included participants with previous ineffective 
treatments and “chronic” PTSD, Schneier and colleagues (2012) found that PE in tandem with 
SSRIs was more effective than PE and placebo among survivors of the World Trade Center 
attack on 9/11. No studies were found that evaluated SSRI in conjunction with psychotherapy for 
military populations.  
Previous PTSD Treatment-Choice Studies  
One solution to increasing attendance and efficacy in treatment for PTSD in combat 
Veterans is to simply ask individuals what treatment they prefer. To this end, treatment-choice 
studies, or those examining what treatments individuals choose and why, afford insight into the 
decision-making process of treatment consumers (Cochran et al., 2008). Clinicians reported a 
more positive patient prognosis when treatment rationales were understood and agreed upon by 
the patient (Addis & Carpenter, 1999).   
Previous treatment-choice studies in PTSD largely focus on treatment for survivors of 
sexual assault (Cochran et al., 2008; Zoellner et al., 2003; Zoelner et al., 2009) and by providing 
vignettes summarizing a fictional patient, why they are seeking treatment, and treatment 
descriptions. In one study comparing treatment choice between PE and sertraline (an SSRI), a 
sample of non-trauma exposed women overwhelmingly chose PE over sertraline. Approximately 
75% of respondents reported perceptions of effectiveness as a reason. In addition, approximately 
half reported that they were weary of medications to treat PTSD (Cochran et al., 2008). These 
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results were partially supported by another study evaluating responses from trauma-exposed 
participants and those without a history of trauma (Pruitt et al., 2012). When participants without 
a history of trauma listened to patient reviews of sertraline and PE, they reported preference for 
PE. However, when trauma-exposed participants responded, they endorsed the use of sertraline 
and PE in combination. This finding was supported when a similar study gave the vignette in 
addition to a measure of PTSD symptoms and treatment choices of PE and Sertraline. All 
respondents endorsed the use of PE, but those with a history of trauma endorsed the use of 
sertraline higher than those without a trauma history (Zoellner et al., 2009). Taken together, these 
studies lend evidence that experience with trauma may alter treatment perception choice.  
Previous studies have looked at “treatment interests” among combat Veterans of Iraq and 
Afghanistan. However, rather than ask about treatment directly, they listed 17 practical domains 
in life (e.g., information on Veterans’ benefits, medication, group therapy) and asked their 
interest in improving them (Sayer et al., 2010). In this study, combat Veterans showed most 
interest in VA benefits and about schooling, employment or job training. The authors suggested 
Veterans were more interested in other practical domains of living and endorsed significantly less 
interest in mental-health treatment options. 
Current Study 
 The current study will apply an exploratory inductive reasoning approach to provide 
basic data that can later support applied research into treatment attendance and adherence among 
military populations. Two samples will represent two distinct populations of military service: 
Vietnam-era combat Veterans and post-9/11 combat Veterans. The first aim of this study is to 
evaluate for endorsement of treatment options after reading a hypothetical vignette of a soldier 
experiencing symptoms consistent of PTSD and look for differences among the two group 
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groups of Veterans. The second aim of this study is to evaluate individual factors and how these 
may relate to treatment choice. Previous literature provides evidence that personality, rurality, 
trauma exposure, and generational cohort influence treatment attendance and adherence. These 
factors will be analyzed with the aim of uncovering potential traits that might predict treatment 
choice.  
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CHAPTER 3: METHOD 
Participants  
 We recruited 218 participants through the online data collection application Mechanical 
Turk (mTurk). Only participants with deployments during either the Vietnam Era (02/28/1961 – 
05/07/1975; DVA, 2017) or Post 9/11 Era (after 09/11/2001; GPO, 2003) were retained for 
analysis, reducing the sample size to 185 (Vietnam Era = 25; Post 9/11 = 160) with 28 women 
who were all Post-9/11 Veterans. Participants received one dollar of credit through mTurk 
reimbursement accounts as compensation. Demographic information by group, including age, 
time in service, number of months deployed, highest obtained military rank, childhood and 
current rurality can be found in Table 1. Also in Table 1 are t-test statistics for group 
comparisons; these two groups differed significantly with Post 9/11 Veterans reporting a 
significantly younger age than Vietnam Veterans, more months deployed, more total time in 
service, and higher obtained rank.  
Materials and Procedure 
Vignette, Treatment Descriptions, and Credibility/Expectancy Questionnaire (CEQ; 
Appendix A).  Participants were initially presented with a fictional vignette briefly describing the 
experience of an individual who returned from combat deployment and is now experiencing 
symptoms of PTSD. The vignette was purposely vague in descriptions to avoid potential 
confounds that could arise from some participants with combat experience relating to the story 
more than others (Foa et al., 2006). The vignette described common themes commonly found in 
Veteran narratives rather than specific details.   
At the end of the vignette, treatment options were presented in random order with 
information about the name of the treatment, description, goals, and potential discomfort. 
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Following each treatment option, the CEQ was presented. The CEQ consisted of six items 
divided into two sets. In Set 1, participants rated each treatment using four Likert-type items on a 
scale from one (not at all logical) to nine (very logical) in their view of credibility of each 
treatment. In Set 2, participants rated the perceived expected efficacy of the treatment using an 
item to measure the participant’s expected decrease in symptoms as described in the vignette. 
Means scores for each set were obtained. The CEQ has demonstrated good reliability across 
multiple populations, including Veteran and college samples (α = .84-.85; Devilly & Borkovec, 
2000). Following the last treatment option and CEQ, participants completed the DUKE, PCL-5, 
BFI, SSOSH, and then a demographics form.  
The Duke Health Profile (DUKE; Appendix B). The DUKE is a 17-item self-report 
measure that consists of six health facets (physical, mental, social, general, perceived health, and 
self-esteem) and four facets of dysfunction (anxiety, depression, pain, and disability). The DUKE 
has been shown to be a reliable brief screener of overall health across multiple domains (α 
= .55-.78; Parkerson, Broadhead, & Tse, 1990).    
 The PTSD Checklist for DSM-5 (PCL-5; Appendix C). The PCL-5 is a 20-item self-
report measure adapted from the original PCL to adhere to diagnostic changes made to the 
diagnosis of PTSD in the DSM-5. Participants were asked to rate items on a five-point Likert-
type scale that indicates severity of PTSD symptoms during the past month. The original PCL 
has consistently demonstrated excellent reliability and validity in multiple populations 
(McDonald & Calhoun, 2010) and specifically within military and Veteran populations (Wilkins, 
Lang, & Norman, 2011). Limited data are available on the psychometrics of the PCL-5 due to its 
recent development. However, an initial study has suggested strong Cronbach’s α of .94 (Liu et 
al., 2014).  
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The Big Five Inventory-10 (BFI-10; Appendix D). The BFI-10 is a 10-item instrument 
that is a shorter version of the original 44-item BFI. This measure assesses personality through 
the lexical Big Five factors of personality (Openness, Conscientiousness, Extraversion, 
Agreeableness, and Neuroticism; John, Naumann, & Soto, 2008). Participants were asked to rate 
on a five-point Likert scale how strongly they agree or disagree with statements about their 
personality. Reliability of the BFI has been shown to be strong in North American samples (α 
= .75 - .90; John et al., 2008), and the mean correlation of .83 between BFI-10 and BFI suggest 
minimal loss of reliability in using the truncated version (Rammstedt & John, 2007). However, 
Rammstedt and John (2007) do suggest an additional item to increase the correlation with the 
original BFI when assessing Agreeableness. This additional item was used due to the anticipated 
impact Agreeableness will have on this study, bringing the total number of items to 11.  
 Self-Stigma of Seeking Help Scale (SSOSH; Appendix E). The SSOSH is a 10-item 
instrument that assesses self-stigma associated with seeking mental health services (Vogel et al., 
2006). Participants were asked to rate on a five-point Likert scale how strongly they agree or 
disagree with statements about seeking mental health services. Reliability of the SSOSH has 
been shown to be strong in civilian (α = .90; Vogel et al., 2006) and military (α = .90; Skopp et 
al., 2012) populations.  
 Demographics (Appendix F). The information on the demographic form asked 
participants to report their age, gender, ethnicity, marital status, education, maternal education, 
branch of military service, years of military service, highest obtained military rank, number of 
combat deployments, time in months total of combat deployments, and rurality. Rurality was 
assessed by asking participants to rate the rurality of both their current and childhood residences 
on a scale of 1 (extremely rural) to 7 (extremely urban).  
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CHAPTER 4: RESULTS 
Preliminary Analyses 
 Descriptive statistics by group (Vietnam, Post 9/11 Veterans) and t-test comparison 
statistics for all measures (i.e., DUKE, PCL-5, BFI, and SSOSH) can be found in Table 2. Post 
9/11 Veterans reported lower self-esteem, higher global PTSD symptoms, and more significant 
distress from symptoms of intrusion and arousal than Vietnam Veterans. Of note, on the PCL-5, 
the averages for both cohorts were above the recommended cut-point for clinical elevation 
(clinical significant cut-point = 33; Weathers et al., 2013). No significant differences were found 
in personality variables (BFI), self-imposed stigma towards seeking mental health services 
(SSOSH), or DUKE domains other than Self-Esteem.  
Differences in Treatment Endorsement by Group 
The first aim of this study was to evaluate whether Vietnam and Post 9/11 Veterans 
differentially endorsed the nine treatment options. To determine if group (Vietnam, Post 9/11) 
was related to treatment endorsement, we analyzed these data using two 2 (group) x 9 
(treatment)mixed model ANOVAs, one for CEQ credibility as the outcome variable and one for 
CEQ expectancy as the outcome variable. The main effect of group on treatment endorsement 
was not significant for either credibility or expectancy. For credibility, Mauchly’s test of 
sphericity showed a significant violation, χ2(35) = 686.44, p < .001. Based on Greenhouse-
Geisser adjustments, F(4.05, 740.18) = 1.01, p = .426. For expectancy, Mauchly’s test of 
sphericity showed a significant violation, χ2(35) = 486.57, p < .001. Based on Greenhouse-
Geisser adjustments, F(5.04, 650.26) = .78, p = .379. Means and standard deviations by group 
can be found in Table 3. 
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Factors Related to Treatment Choice 
The second aim of this study was to evaluate individual factors and how they may relate 
to treatment choice. Because we did not find differences in treatment choice based on sample, we 
collapsed across both groups for subsequent analyses (N = 185). The eight treatments and the no-
treatment option were evaluated based on credibility and expectancy with several personality, 
demographic, and mental health variables entered as potential predictor variables. Since no well-
established theories on patient-treatment selection are available for comparison, we did not use 
forced entry of multiple linear regression (Studenmund & Cassidy, 1987). In addition, suppressor 
effects and increase for Type II error are undesirable since this exploratory study could provide 
data for hypothesis testing in future studies. Therefore, we used the backward entry method to 
retain the highest number of potential predictor variables. These variables can be removed 
through forced-entry hypothesis testing in later studies (Field, 2013). Consequently, multiple 
regression analyses were conducted for credibility and Expectancy (See Tables 4-12) 
CPT (Table 4) credibility was predicted by lower self-stigma, lower symptoms of 
depression, and less reactivity and arousal symptoms of PTSD, and a lower endorsement of 
extroversion. Higher endorsement of physical pain and avoidance symptoms were predictive of 
credibility of CPT. Expectancy of individual symptom decrease was predicted by higher 
intrusion and avoidance symptoms of PTSD and less stigma, anxiety, and arousal symptoms of 
PTSD. The other treatment with strong VA support, PE (Table 5), had predictive credibility only 
by two variables. PE credibility was predicted by lower scores on physical pain and stigma. 
Expectancy in symptom reduction was stronger in those higher in intrusion symptoms of PTSD 
and less symptoms of anxiety.  Credibility of PE in conjunction with D-Cycloserine (Table 6), 
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theorized to increase speed of habituation, was predictive by a high endorsement of avoidance 
symptoms, less symptoms of arousal, and less self-induced stigma. These factors were also 
shown in expectancy of symptom reduction, with the addition of more combat deployments and 
higher depression.  
 EMDR (Table 7) was the only treatment where higher endorsement of self-induced 
stigma was related to higher rates of credibility and expectancy. Expectancy of symptom 
reduction was only additionally predicted by less negative alterations in cognition and mood.  
Credibility was also predicted by fewer number of combat deployments in addition to lower 
endorsement of negative alterations in cognitions and mood after trauma and higher endorsement 
of self-induced stigma.  
SSRI medication alone (Table 8) was only predicted by physical difficulties, specifically 
higher endorsement of pain and disability. Expectancy was also predictive by higher pan 
endorsement, in addition those with higher endorsement of avoidance symptoms of PTSD and 
more likely to be supported by those who are younger in age.  When SSRI medication is used in 
combination with psychotherapy (Table 9), less self-induced stigma, less anxiety, higher 
depression and higher avoidance symptoms become predictive factors. Symptom expectancy was 
predicted by less stigma, less intrusion symptoms, and higher avoidance, anxiety, and physical 
pain.  
The use of WEP as treatment (Table 10) yielded credibility predicted by higher 
education, currently more rural, fewer deployments, and less endorsement of arousal. 
Expectancy of symptoms reduction was again predicted by higher education, and fewer number 
of deployments. Symptoms reduction expectancy was predicted by lower endorsement, fewer 
number of deployments, lower endorsement of overall psychological well-being and less 
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negative alterations of cognition after trauma. Individuals who were likely to endorse WEP 
favorably were also more likely to endorse personality traits consistent with agreeableness.  
For WT (Table 11), endorsement of credibility was predicted by fewer symptoms of 
arousal, less depression, less physical pain, and fewer number of deployments. However, lower 
endorsement of overall psychological well-being was also predictive of higher WT endorsement. 
These individuals were also more likely to currently live in more rural environments. Expectancy 
in symptoms reduction was again predicted by lower endorsement of overall psychological well-
being and fewer symptoms of psychological arousal.  A current rural environment was predictive 
of expectancy, as with credibility, although a childhood urban environment was observed 
predictive of expecting higher symptom reduction.  
The option to not seek treatment (Table 12) was endorsed as more credible by those with 
less arousal symptoms, less physical pain, less depression, and fewer deployments. Conversely, 
these individuals were lower on overall psychological well-being. They also endorsed more rural 
current environment. In expectancy of symptom reduction, a more rural current environment was 
endorsed, however a more childhood urban environment. A lower endorsement of negative mood 
was predictive of higher expectancy in reduction, as was lower endorsement of general 
psychological well-being.  
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CHAPTER 5: DISCUSSION 
The purpose of the current study was to explore Veteran reports of perceived credibility 
of common and novel PTSD treatments and their expectancy of symptom reduction through 
these treatments. We aimed to evaluate previous studies suggesting that treatments have different 
outcome and attendance rates between Vietnam and Post-9/11 Veterans (Chard et al., 2010). 
Additionally, we sought to determine what factors might influence treatment choice, with the 
end-goal of improving treatment attendance and completion.  
Treatment Endorsement   
 Data from this study did not reveal differences in either credibility or expectancy between 
Vietnam and Post 9/11 Combat Veterans for any treatments. Previous studies have suggested that 
cohort is a stronger predictive factor of treatment choice than psychiatric symptoms, with 
Vietnam Veterans more likely to seek treatment (Erbes et al., 2009) and to benefit from 
treatment (Resnick, 2009) than Post 9/11 Veterans. Support for the assumption that strength of 
endorsement regarding treatment choice would also differ significantly and offer predicative 
value (Cochran et al, 2008) was not provided by this study.   
 Perhaps contributing to these inconclusive findings is the lower than expected 
endorsement of treatment when qualitatively comparing our sample to prior samples (e.g. Pruitt 
et al., 2012). Although we used a different metric than prior studies, other studies (e.g., 
Rothbaum et al., 2006) have reported better optimism that different treatments will work than in 
our study. Statistically, the narrowing range of these data may impact predictive significance. 
Sampling may also be a contributor to nonsignificant findings, as previous studies have used 
Veterans right before or during treatment or university samples made up primarily of female 
participants. In contrast, we used an online sample of Veterans who were mostly men and who 
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may have had a range of exposure to treatment in terms of the kinds of treatment and when they 
were in treatment that serveas confounds.  
 Research also has shown different results among female samples with those who have no 
trauma history endorsing PE higher than SSRI medication alone and combining PE with SSRIs 
(Cochran et al., 2008) and those with a trauma history endorsing the combination of PE and 
SSRI higher (Pruitt et al., 2008). Trauma history was not evaluated in the current study due to 
online assessment and safety concerns, although all had experienced at least one combat 
deployment. Additionally, most of the participants in this study were men (exclusively men in 
the Vietnam sample).  
Treatment Endorsement Predictors  
 Prior studies have shown that adherence to and preference for treatment options are 
associated with patient factors such as symptoms of depression among Vietnam Veterans (Erbes 
et al., 2009), PTSD symptoms among women with trauma history (Cochran et al., 2008), and 
personality traits such as conscientiousness and agreeableness predicting better treatment 
adherence Bruce et al., 2010). Within our sample, these variables and endorsement of treatment 
were inconsistent with prior treatment outcome and treatment choice studies, which is discussed 
in detail below. For clarity, we included a summary of model prediction findings in Table 13. 
 Prior treatment choice studies have shown that, among women, trauma history and PTSD 
symptoms were predictive factors of treatment choice (Cohchran et al., 2008; Pruitt et al., 2012). 
In this study, total PTSD symptom presentation did not yield the same strength of endorsement. 
However, when evaluating endorsement of each specific criterion within the diagnosis criteria as 
measured by the PCL-5, significant predictive value was yielded from these scores. For instance, 
avoidance symptoms are one of the hallmark symptoms of PTSD and yielded both positive and 
  
48 
negative predictive value across treatments. Those who scored higher on symptoms of avoidance 
were shown to have higher endorsements of CPT, SSRI alone and in conjunction with 
psychotherapy, and D-Cycloserine with PE. The descriptions of these treatments stated that 
discomforts would occur in session and/or medication would assist in coping/extinguishing the 
fear response. Qualitatively, this could suggest that Veterans with higher endorsement of 
avoidant symptoms perceived benefits to treatment focusing on confronting the trauma but 
wanted assistance in coping with the trauma from either their therapist or medication. Similarly, 
symptoms of arousal and reactivity (e.g., hypervigilance) were negative predictors of CPT, PE 
with D-Cycloserine, WT, and WEP.  
 One unexpected contributor of these data is the impact of physical ailments on selection 
of mental health treatment. Physical factors such as pain and disability were not considered in 
review of prior treatment choice studies. Experiencing physical pain was a negative predictor of 
treatments where physical discomfort could be indicated in the provided description, such as PE 
and WT. Conversely, physical pain was a positive predictor of treatments with low physical 
expectations or involving medications (CPT, SSRI alone, SSRI w/ therapy), meaning that those 
in more physical pain were more likely to endorse treatments they perceived carried less physical 
demands or discomfort.  
 The role of stigma in treatment is frequently cited in the literature across virtually all 
populations. Specifically among military populations, concerns of career advancement and 
perceptions of subordinates and superiors are prevalent. As a Veteran sample, our population 
was no longer currently serving in the military and were less likely to experience these external 
factors due to increased privacy regulations in the civilian sector. Therefore, we chose a measure 
that limited stigma to self-induced stigma that asked questions about self-evaluation. Stigma 
  
49 
endorsement had a negative relationship with treatments focusing on psychotherapy apart from 
EMDR, indicating that, for the most part, the less stigma one felt, the more appealing 
psychotherapies were. One possible explanation for the EMDR endorsement compared to other 
psychotherapies was the description of EMDR participants read. The description used 
highlighted the bilateral tracking in conjunction with processing memories. EMDR description 
did not explicitly state, like other psychotherapies, these memories would be shared, discussed, 
or vocalized. This could have been viewed by participants as a method of seeking treatment and 
not having to risk the potential of increased stigmatization by disclosing painful or embarrassing 
narratives or emotions.  
  The proposed value of evaluating treatment choice is the idea that through the process of 
evaluation and selection the patient assumes partial responsibility, and adherence increases with 
subsequent improvement (Carpenter et al., 1999). Currently, the dissemination efforts of policy 
makers, agencies, and organizations are for providers to only provide evidence-based treatments 
(EBTs; Resnick et al., 2009). However, some EBTs do not lead to the same results in real-world 
applications as they do in controlled studies, and many researchers are investigating possible 
explanations. If treatment choice carries the weight of influence as proposed by previous 
research (e.g., Milliken et al., 2007), then one of the potential negating factors of effective 
treatment is simply that the patient did not like it for any number of reasons.  
 The view of the patient actively choosing a treatment that addresses presenting problems 
was assumed by Carpenter and colleagues (1999) but never validated. The data found in the 
current study could lend evidence that patients endorse treatments that enable, rather than treat, 
symptoms of psychological distress. For example, CPT does not focus on behavioral exposure to 
anxiety-provoking stimuli to the same degree as PE. Instead, CPT focuses more on cognitive 
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alterations and working through “stuck points” with patients. The predictive factors of choosing 
CPT were high avoidance and intrusion symptoms and lower depression.  
Comfort seeking considerations in treatment may be different throughout the lifespan. 
Age was only predicative of SSRI medication alone as treatment. Previous studies (e.g., Zoellner 
et al., 2003) suggest medication was more likely endorsed by those who considered the time 
commitment of weekly sessions too burdensome, and this could also be reflective in our sample. 
Considering the effectiveness of SSRI medications alone with Veterans, this convenience could 
also be an enabling behavior. Qualitative explanations were not collected from participants, 
which could have provided valuable information into the rationale behind treatment choice.   
 Symptoms predictive of WT and WEP choice were unique from other treatments in that a 
lower general overall psychological well-being was indicated. The DUKE Mental Health domain 
is calculated using scores relating to self-esteem, overall mood, motivation, and nervousness. 
Symptoms more consistent with a definitive diagnosis were not predictive, or as strong, as 
overall well-being. The description did not suggest, as with other treatments, that a specific 
symptom or a disorder would be targeted. The patient symptoms description and lack of 
predictability with other symptoms could be indicative of a need for an experiential process for 
self-fulfillment rather than treatment of a specific disorder. Predicative factors of WEP were also 
higher education and a shift from urban childhood setting to rural adult setting, which was not 
seen in other treatments. This would appear to be more consistent with integration difficulties as 
described in the literature (Shays, 2010), and other treatments described in this study would be 
inappropriate due to targeted focus.  
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Limitations 
 The data collected for this study was done so through mTurk, the online data collection 
service through Amazon Web Services. Verification of factors measured in this study could not 
be absolutely confirmed. The data was examined for unlikely combinations in demographic 
reporting (e.g., years of service, year of first deployment, current age), and no improbable 
combinations were detected. The use of mTurk, as with any on-line distance study, raises 
concerns of requesting information that may elicit strong emotional responses. For this reason we 
did not ask about prior trauma history or prior exposure to treatment. This information has 
yielded mixed results in previous studies but may have shown relationships in this study that 
could have provided useful information.  
 The use of mTurk may have also allowed for selection bias that we are unable to detect. 
Our participants are all part of an online Web Service system and are compensated for their time. 
The ability to do so, or the necessity to do so, may have limited both the internal and external 
validly of our study. That a significant majority of our sample scored over the clinical cut-off for 
symptoms of PTSD and avoidance behaviors is a cardinal symptom, which also limits external 
validity (generalizability). Additionally, we did not ask about service connection status or VA 
benefits status. This information could have provided insight into ability to use this sample as a 
comparison from VA studies. 
Future Directions 
The current study was exploratory in nature aimed at providing information for future 
hypothesis testing. This information, if confirmed by later studies following patient progress, 
could assist in creating predictive models for real-world applications to improve treatment 
adherence. Additionally, this information could benefit future treatment studies by examining the 
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factors that lead to a patient’s expectation of treatment and considering their strength of actual 
treatment adherence and efficacy. Another potential future direction would be to use predictive 
data as means of understanding why certain populations choose each treatment. If those factors 
are understood better, then treatments could be modified to adapt to these differences. 
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Table 1 
Descriptive Statistics and t-test Statistics for Selected Demographic Variables 
 
 Group   
 Vietnam (n = 25) Post 9/11 (n = 160)   
 
Demographic 
 
M 
 
(SD) 
 
Range 
 
M 
 
(SD) 
 
Range 
t for Group 
Contrast 
 
p-value 
Age 65.48  2.93     61-71 31.31 4.66     21-40 49.34 <.001 
Years in Service 3.76 4.29 2-21 7.34 3.94 4-24 4.18 <.001 
Total Months Deployed 12.12 5.26 4-32 14.64 7.24 2-37 2.11 .041 
Number of Deployments 1.12 0.44 1-3 2.07 1.01 1-6 7.99 <.001 
Highest Obtained Rank 5.16 2.72 3-17 5.91 2.51 3-16 1.37 .173 
Rurality in Childhood 2.32 1.41 1-7 4.14 1.35 1-6 6.23 <.001 
Current Rurality 4.27 1.31 2-7 3.13 1.08 1-5 6.63 <.001 
Note. t for group contrast with 183 df. 
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Table 2 
Descriptive Statistics and t-test Statistics for Mental Health, Personality, and Stigma Measures  
 
 Group   
 Vietnam (n = 25) Post 9/11 (n = 160)   
 
Measure 
 
M 
 
(SD) 
 
Range 
 
M 
 
(SD) 
 
Range 
t for Group 
Contrast 
 
p-value 
DUKE          
   Physical Health 69.20 25.97 10-100 73.50 20.07 10-100 0.96 .341 
   Mental Health 67.20 15.95 50-100 71.75 16.62 30-100 1.28 .202 
   Social Health  56.00 14.72 30-100 48.44 18.80 10-100 1.91 .057 
   General Health 64.13 14.22 40-93.33 64.56 13.03 30-100 0.15 .888 
   Anxiety  40.65 13.67 0-66.64 43.11 19.25 0-83.33 0.79 .437 
   Depression 38.40 12.14 10-50 38.44 14.86 10-80 0.01 .989 
   Pain 46.00 35.12 0-100 34.69 29.67 0-100 1.73 .086 
   Disability  --- --- --- 4.06 15.83 0-100        --- --- 
   Self-Esteem  71.60 17.94 40-90 60.44 18.30 20-100 2.84 .005 
PCL-5 Total 42.60 12.67 14-60 49.26 12.69 0-75 2.44 .016 
   Intrusion Symptoms 3.00 0.75 1.8-4.4 3.4 0.68 1-5 2.64 .009 
   Avoidance Symptoms 3.26 1.02 1.5-4.5 3.55 0.79 1-5 1.67 .096 
   Alterations in Mood 3.20 0.73 1.71-4 3.47 0.70 1-4.71 1.83 .070 
   Alterations in Arousal 3.11 0.59 1.67-4 3.47 0.69 1-4.67 2.46 .015 
BFI         
   Openness  4.80 2.58       2-10 5.45 2.61 2-10 1.16 .247 
   Contentiousness  6.81 2.40 4-10 6.70 2.28 2-10 0.20 .840 
   Extraversion 5.96 1.86 2-8 6.03 2.12 2-9 0.15 .874 
   Agreeableness  5.52 1.94 3-8 5.79 1.99 3-10 0.64 .521 
   Neuroticism  6.76 2.07 1-10 6.63 2.11 2-10 0.29 .766 
SSOSH 28.72 5.61 13-42 28.89 5.95 12-42 0.13 .895 
Note. DUKE = Duke Health Profile; PCL-5 = Title PTSD Checklist for DSM-5; BFI = Big Five Inventory; SSOSH = Self-Stigma of 
Seeking Help Scale; t for group contrast with 183 df. 
  
TREATMENT CHOICE  71 
 
Table 3 
Descriptive Statistics for Credibility and Expectancy by Group and Treatment  
 
 Credibility Expectancy 
 Vietnam (n = 25) Post 9/11 (n = 160) Vietnam (n = 25) Post 9/11 (n = 160) 
Treatment Option M (SD) M (SD) M (SD) M (SD) 
CPT 3.00 1.36 3.31 1.25 35.20 34.90 39.56 26.31 
PE 3.70 1.41 3.59 1.04 40.40 25.74 42.00 19.16 
EMDR 1.84 1.17 2.00 1.25 18.40 18.64 19.31 17.09 
SSRI 2.63 1.22 2.63 1.35 18.40 18.86 27.38 21.26 
WEP 3.69 1.52 3.90 1.48 44.80 23.12 42.06 22.43 
WT 4.39 1.93 4.50 1.55 48.80 24.72 59.13 21.47 
D-Cycloserine 3.43 0.88 3.26 1.41 37.20 23.19 37.88 20.04 
SSRI/Therapy Combo 3.29 1.16 3.21 1.41 38.80 16.41 37.88 21.90 
No Treatment 1.77 0.97 1.32 0.89 17.60 18.32 15.88 20.45 
Note. CPT = Cognitive Processing Therapy; PE = Prolonged Exposure; EMDR = Eye Movement Desensitization and Reprocessing; 
SSRI = Selective Serotonin Reuptake Inhibitor; WEP = Wilderness Experience Program; WT = Wilderness Therapy.  
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Table 4 
 
Multiple Regression Model Outcomes for Cognitive Processing Therapy  
 
 B SE B Beta t p 
Credibility       
   Constant 6.01 0.71  8.42 <.001 
   SSOSH -0.07 0.02 -0.31 3.71 <.001 
   BFI Extroversion -0.08 0.04 -0.14 2.01 .047 
   DUKE Depression -0.03 0.08 -0.39 4.16 <.001 
   DUKE Pain 0.02 0.01 0.38 3.97 <.001 
   PCL-5 Avoidance 0.51 0.15 0.33 3.47 .001 
   PCL-5 Alterations in Arousal -0.36 0.17 -0.19 2.11 .036 
   R2 = .216      
Expectancy       
   Constant 58.015 12.041  4.82 <.001 
   DUKE Anxiety  -0.261 0.135 -0.176 1.93 .055 
   SSOSH -1.337 0.409 -0.286 3.27 .001 
   PCL-5 Intrusion Symptoms 13.762 4.371 0.357 3.15 .002 
   PCL-5 Avoidance 5.502 2.996 0.165 1.84 .068 
   PCL-5 Alterations in Arousal -10.121 4.59 -0.253 2.21 .029 
   R2 = .160      
Note. SSOSH = Self-Stigma of Seeking Help Scale; BFI = Big Five Inventory; PCL-5 = PTSD 
Checklist for DSM-5; DUKE = Duke Health Profile. 
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Table 5 
 
Multiple Regression Model Outcomes for Prolonged Exposure Therapy  
 
 B SE B Beta t p 
Credibility       
   Constant 4.84 0.01  12.71 <.001 
   DUKE Pain  -0.01 0.03 -0.31 4.05 <.001 
   SSOSH -0.03 0.02 -0.16 2.05 .042 
   R2 = .162      
Expectancy      
   Constant 41.44 6.83  6.09 <.001 
   DUKE Anxiety -0.35 0.09 -0.33 4.05 <.001 
   PCL-5 Intrusion Symptoms 4.57 2.26 0.16 2.02 .045 
   R2 = .083      
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE 
= Duke Health Profile. 
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Table 6 
Multiple Regression Model Outcomes for D-Cycloserine and PE Combination  
 B SE B Beta t p 
Credibility       
   Constant   6.59 0.47  14.029 <.001 
   PCL-5 Alterations in 
Arousal -0.70 0.15 -0.36 4.76 <.001 
   SSOSH -0.13 0.01 -0.57 9.05 <.001 
   PCL-5 Avoidance 0.77 0.12 0.47 6.46 <.001 
   R2 = .429      
Expectancy      
   Constant 77.637 6.825  11.375 <.001 
   SSOSH -2.046 0.223 -0.59 9.169 <.001 
   PCL-5 Avoidance 8.208 1.64 0.332 5.005 <.001 
   PCL-5 Intrusion Symptoms -9.937 1.994 -0.348 4.983 <.001 
   Number of Deployments 3.048 1.126 0.15 2.707 .007 
   DUKE Depression 0.46 0.086 0.326 5.347 <.001 
   R2 = .473      
 Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE 
= Duke Health Profile. 
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Table 7 
Multiple Regression Model Outcomes for Eye Movement Desensitization and Reprocessing  
 B SE B Beta t p 
Credibility       
   Constant 4.09 0.61  6.71 <.001 
   SSOSH 0.05 0.02 0.21 2.80 .006 
   Number of Deployments -0.21 0.09 -0.17 2.40 .018 
   PCL-5 Alterations in Mood -0.76 0.14 -0.43 5.48 <.001 
   R2 = .186      
Expectancy       
   Constant  15.97 7.14  2.24 .026 
   SSOSH 0.90 0.23 0.31 3.87 <.001 
   PCL-5 Alterations in Mood -6.60 1.96 -0.27 -3.37 .001 
   R2 = .103      
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5.  
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Table 8 
Multiple Regression Model Outcomes for SSRI Medication 
 B SE B Beta t p 
Credibility       
   Constant 2.31 0.15  15.64 <.001 
   DUKE Pain 0.01 0.01 0.169 2.33 .021 
   DUKE Disability 0.02 0.01 0.163 2.24 .026 
   R2 = .054      
Expectancy       
   Constant 13.63 8.68  1.57 .118 
   DUKE Pain 0.12 0.05 0.18 2.52 .012 
   PCL-5 Avoidance 5.65 1.82 0.22 3.11 .002 
   R2 = .122      
Note. PCL-5 = PTSD Checklist for DSM-5; DUKE = Duke Health Profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT CHOICE  78 
 
Table 9 
Multiple Regression Model Outcomes for SSRI Medication and Therapy Combination 
 B SE B Beta t p 
Credibility       
   Constant 4.94 0.41  12.18 <.001 
   SSOSH -0.14 0.02 -0.59 9.74 <.001 
   PCL-5 Avoidance 0.26 0.09 0.16 3.05 .003 
   DUKE Anxiety -0.04 0.01 -0.52 6.15 <.001 
   DUKE Depression 0.08 0.01 0.80 10.75 <.001 
   R2 = .578      
Expectancy      
   Constant 73.60 5.94  12.39 <.001 
   DUKE Pain 0.14 0.04 0.20 3.56 <.001 
   SSOSH -2.95 0.21 -0.83 14.04 <.001 
   PCL-5 Avoidance 17.50 1.42 0.68 12.32 <.001 
   DUKE Anxiety 0.42 0.07 0.37 5.88 <.001 
   PCL-5 Intrusion 
Symptoms -10.51 1.741 -0.35 6.04 <.001 
   R2 = .646      
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE 
= Duke Health Profile. 
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Table 10 
Multiple Regression Model Outcomes for Wilderness Experience Program  
 B SE B Beta t p 
Credibility      
   Constant  6.17 0.70  8.82 <.001 
   PCL-5 Alterations in 
Arousal -0.58 0.15 -0.27 3.87 <.001 
   Education  0.26 0.10 0.19 2.66 .009 
   Number of Deployments -0.26 0.10 -0.17 2.48 .014 
   Current Rurality -0.19 0.08 -0.16 2.34 .020 
   R2 = .141      
Expectancy      
   Constant 74.69 12.64  5.91 <.001 
   Education 3.33 1.45 0.16 2.27 .025 
   Months of Deployment -0.48 0.22 -0.15 2.19 .030 
   DUKE Mental Health -0.20 0.09 -0.15 2.12 .035 
   BFI Agreeableness 1.56 0.77 0.14 2.02 .045 
   PCL-5 Intrusion Symptoms -9.24 2.15 -0.30 4.30 <.001 
   R2 = .162      
Note. SSOSH = Self-Stigma of Seeking Help Scale; BFI = Big Five Inventory; PCL-5 = PTSD 
Checklist for DSM-5; DUKE = Duke Health Profile. 
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Table 11 
Multiple Regression Model Outcomes for Wilderness Therapy 
 B SE B Beta t p 
Credibility      
   Constant  9.31 0.90  10.34 <.001 
   PCL-5 Alterations in 
Arousal -0.42 0.16 -0.18 2.63 .009 
   DUKE Pain -0.01 0.01 -0.18 2.09 .038 
   DUKE Mental Health -0.02 0.01 -0.16 2.34 .020 
   Current Rurality -0.21 0.09 -0.16 2.29 .023 
   Number of Deployments -0.27 0.11 -0.17 2.54 .012 
   DUKE Depression -0.02 0.01 -0.17 1.99 .048 
   R2 = .204      
Expectancy      
   Constant 98.86 13.89  7.12 <.001 
   Childhood Rurality 2.40 1.07 0.16 2.25 .026 
   DUKE Mental Health -0.21 0.10 -0.16 2.13 .035 
   Current Rurality -3.71 1.31 -0.21 2.83 .005 
   PCL-5 Alterations in Mood -6.77 2.26 -0.21 2.99 .003 
   R2 = .118      
Note. PCL-5 = PTSD Checklist for DSM-5; DUKE = Duke Health Profile. 
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Table 12 
Multiple Regression Model Outcomes for No Treatment 
 B SE B Beta t p 
Credibility      
   Constant  3.70 0.28  13.24 <.001 
   DUKE Pain 0.01 0.00 0.17 2.46 <.001 
   PCL-5 Avoidance -0.33 0.08 -0.30 4.16 .047 
   DUKE Anxiety 0.01 0.00 0.23 2.92 <.001 
   PCL-5 Intrusion Symptoms -0.55 0.10 -0.43 5.68 <.001 
   R2 = .23      
Expectancy      
   Constant 58.02 12.04  4.82 <.001 
   SSOSH -0.26 0.14 -0.18 1.93 .055 
   PCL-5 Avoidance -1.34 0.41 -0.29 3.27 .001 
   DUKE Anxiety 13.76 4.37 0.38 3.15 .002 
   PCL-5 Intrusion Symptoms 5.50 3.01 0.17 1.84 .068 
   R2 = .118      
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE 
= Duke Health Profile. 
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Table 13 
Summary of Significant Model Findings Across all Nine Treatment Options 
Note. C = Credibility; E = Expectancy; CPT = Cognitive Processing Therapy; PE = Prolonged Exposure; Meds + PE = D-Cycloserine 
with Prolonged Exposure; EMDR = Eye Movement Desensitization and Reprocessing; SSRI = Selective Serotonin Reuptake Inhibitor; 
WEP = Wilderness Experience Program; WT = Wilderness Therapy; No Tx = No treatment; DUKE = Duke Health Profile; PCL-5 = 
PTSD Checklist for DSM-5; BFI = Big Five Inventory; SSOSH = Self-Stigma of Seeking Help Scale.  
 
 
 
 
 
CPT 
 
PE 
Meds + 
PE 
 
EMDR 
 
SSRI 
SSRI + 
therapy 
 
WEP 
 
WT 
 
No Tx 
Variable C E C E C E C E C E C E C E C E C E 
Education             + +     
Childhood Rurality                +   
Current Rurality             -  - -   
Number of Deployments      + -      -  -    
Months of Deployment              -     
DUKE Mental Health              - - -   
DUKE Anxiety   -  -       - +     + + 
DUKE Depression -     +     +    -    
DUKE Pain +  -      + +  +   -  +  
DUKE Disability          +          
PCL-5 Intrusion Symptoms  +  +  -      -  -   - + 
PCL-5 Avoidance  + +   + +    + + +     - - 
PCL-5 Alterations in Mood       - -        -   
PCL-5 Alterations in Arousal - -   -        -  -    
BFI Extraversion -                  
BFI Agreeableness               +     
SSOSH - - -  - - + +   - -      - 
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Appendix A 
Vignette, Treatment Descriptions, and Credibility/Expectancy Questionnaire  
 
Vignette  
 
Instructions: Please read the following story. You will be asked for your opinion on the next 
several pages.  
 
Peyton enlisted in the United States Military and shortly after was assigned to a six-
month tour in a combat zone. During the deployment Peyton’s daily routine was unpredictable, 
with frequent shifts between active combat and periods of calm. However, Peyton knew the 
danger inherent in the environment and was always vigilant to potential threats and ready to act 
at a second’s notice. After deployment, Peyton immediately returned to civilian routines. Shortly 
after returning home, Peyton began experiencing physical reactions to sights, sounds, and smells 
that were similar to those experienced during deployment. Peyton then began to avoid reminders 
of the deployment because the physical reactions were too stressful. Peyton’s personal life was 
also impacted, as activities that were once enjoyed were no longer interesting. Peyton felt the 
need to always be on guard, which led to trouble concentrating, always being on the lookout for 
threats, and constant irritability. Peyton began staying home more and increasingly cutting back 
on the number of family and friends seen on a regular basis. A few of Peyton’s closest family and 
friends noticed this change and suggested Peyton should seek mental-health treatment.  
  
Treatment Descriptions 
 
Instructions: Consider Peyton’s story and the following treatment options. After reading each 
treatment option, please answer the questions about each treatment choice.  
 
Name of treatment: Cognitive Processing Therapy (CPT)  
Description: CPT typically includes 12 weekly sessions and involves discussion, learning 
coping skills, and writing about the event.  
 
Goals: CPT primarily focuses on the thoughts and emotions surrounding the traumatic event 
to alleviate the psychological distress impacting current thoughts, emotions, and behaviors.  
 
Potential Discomforts: It is possible that discomfort is experienced during treatment as the 
individual is asked to recall thoughts and emotions related to the event.  
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Name of treatment: Prolonged Exposure Therapy (PE)  
Description: PE typically includes 8-15 weekly sessions and involves imagined and real 
exposure to situations, objects, and memories. 
 
Goals: PE primarily focuses on the behaviors that maintain symptoms by evaluating 
avoidance behaviors and then confrontation to what is avoided. Confrontation occurs 
repeatedly until negative thoughts and bodily sensations from anxiety are no longer 
experienced.  
 
Potential Discomforts: Confrontations will initially trigger feelings of anxiety.   
 
 
Name of treatment: Eye Movement Desensitization and Reprocessing (EMDR)  
Description: EMDR typically includes 8-15 weekly sessions and focuses on processing 
distressing memories while following the therapist’s fingers with his/her eyes left to right.  
 
Goals: The goal of EMDR is to reduce negative thoughts and emotions associated with the 
traumatic event.  
 
Potential Discomforts: It is possible that discomfort is experienced during treatment as the 
individual is asked to recall thoughts and emotions related to the event.  
 
Name of treatment: Selective Serotonin Reuptake Inhibitors (SSRIs)   
Description: SSRIs are prescription medications that increase the amount of serotonin in the 
brain. Typically, treatment involves taking a pill once daily.   
 
Goals: SSRIs are prescribed to alleviate distress through increasing mood-enhancing 
chemicals in the brain.    
 
Potential Discomforts: Side effects may include nausea, decreased sexual interest, and feeling 
drowsy. Although, these side effects do not occur in everyone.  
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Name of treatment: Wilderness Experience Program (WEPs)  
Description: WEPs are a form of treatment through using natural setting to “decompress” 
from a traumatic event. Typically this occurs through an extended hiking, kayaking, or 
mountain climbing trip. 
 
Goals: The goal is for the individual to remove him/herself from stressors found in society and 
allows time to process the event at his/her own pace.  
 
Potential Discomforts: Discomforts may vary depending on the type of experience in the 
wilderness that is chosen.   
 
Name of treatment: Wilderness Therapy Programs (WT)  
Description: WEPs are a form of treatment through using natural setting to “decompress” 
from a traumatic event. Typically this occurs through an extended hiking, kayaking, or 
mountain climbing trip and includes periodic in-person or electronic therapy (e.g. video chat, 
email) to assist in processing.  
 
Goals: The goal is for the individual to remove him/herself from stressors found in society and 
allows time to process the event at his/her own pace.   
 
Potential Discomforts: Discomforts may vary depending on the type of experience in the 
wilderness that is chosen.   
 
Name of treatment: Medication-Assisted Therapy   
Description: Individuals take an antibiotic medication 30 minutes before each therapy session. 
The antibiotic medication has been shown to assist in fear extinction when used during 
treatment sessions.  
 
Goals: The goal is to increase the effectiveness of each treatment session.    
 
 
Potential Discomforts: The medication does not alleviate potential discomfort during the 
course of the psychological treatment caused by recalling stressful events.  
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Name of treatment: antidepressant medication with traditional talk therapy  
Description: Individuals take a daily antidepressant medication while attending traditional 
weekly sessions of traditional talk therapy.  
 
Goals: The goal is to decrease symptoms that are experienced so that focus can be placed on 
psychological treatment.  
 
 
Potential Discomforts: Discomforts from therapy may be significantly alleviated, but you may 
experience the side-effects of the medication which can include nausea, decreased sexual 
interest, and feeling drowsy.  
 
No treatment  
Description: Some individuals do not seek treatment find strategies to manage and overcome 
symptoms themselves. Some individuals are successful while others are not and symptoms are 
maintaining for a lifetime. There is no “typical” time of recovery.  
 
Potential Discomforts: Discomforts vary across individuals.  
 
 
Credibility/Expectancy Questionnaire  
These questions will be asked at the end of each treatment description. 
 
1.  How logical does the treatment described to you seem?  
 
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
 
 
2.  How successfully do you think this treatment will be in reducing symptoms?  
 
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
 
 
3. How confident would you be in recommending this treatment to a friend?  
  
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
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4.  How much improvement in symptoms do you think will occur?  
 
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
 
5.  How much do you really feel that this treatment will help reduce symptoms?  
 
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
 
6.  How much improvement in symptoms do you really feel will occur from this treatment?  
 
1------------2------------3-----------4------------5------------6------------7 
 Not at all                                                                                            Extremely  
 
7. Please rate the following: 
 
 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
By the end of the treatment 
period, how much 
improvement in symptoms do 
you think will occur?  
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Appendix B 
 
Duke Health Profile 
  
Instructions: Here are some questions about your health and feelings. Please read each question 
carefully and check your best answer. You should answer the questions in your own way. There 
are no right or wrong answers.  
 
 Yes, 
describes me 
exactly 
Somewhat 
describes me 
No, doesn’t 
describe me 
at all 
1. I like who I am……………………………………..    
2. I am not an easy person to get along 
with…………………………………………………… 
   
3. I am basically a health 
person……………………............................................ 
   
4. I give up too easily…………………………………    
5. I have difficult 
concentrating………………………………………… 
   
6. I am happy with my family 
relationships………………………………………….. 
   
7. I am comfortable being around 
people…………………………………………………. 
   
 
TODAY would you have any physical trouble or difficulty:  
 None Some A Lot 
8. Walking up a flight of stairs………………………    
9. Running the length of a football field…………….    
 
During the PAST WEEK: How much trouble have you had with:  
 None Some A Lot 
10. Sleeping……………………………………………    
11. Hurting or aching in any part of your body……..    
12. Getting tired easily………………………………..    
13. Feeling depressed or sad………………………….    
14. Nervousness……………………………………….    
 
During the PAST WEEK: How often did you:  
 None Some A Lot 
15. Socialize with other people (talk or visit with 
friends or relatives)…………………………………… 
   
16. Take part in social, religious, or recreation 
activities (meetings, church, movies, sports, parties).  
   
 
During the PAST WEEK: How often did you:  
 None 1-4 Days 5-7 Days 
17. Stay in your home, nursing home, or hospital 
because of sickness, injury, or other health problem.  
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Appendix C 
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Appendix D 
Big Five Inventory-10 
 
Instructions: Please circle the number for each item that best describes how well you feel 
following statements describe your personality. 
 
I see myself as someone 
who… 
 
Disagree 
strongly 
 
Disagree 
a little 
Neither 
agree nor 
disagree 
 
Agree a 
little 
 
Agree 
strongly 
… is reserved 1 2 3 4 5 
… is generally trusting 1 2 3 4 5  
… tends to be lazy 1 2 3 4 5 
… is relaxed, handles stress 
well 1 2 3 4 5 
… has few artistic interests 1 2 3 4 5 
… is outgoing, sociable 1 2 3 4 5 
… tends to find fault with 
others 1 2 3 4 5 
… does a thorough job 1 2 3 4 5 
… gets nervous easily 1 2 3 4 5 
… has an active imagination 1 2 3 4 5 
… is considerate and kind to 
almost everyone 1 2 3 4 5 
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Appendix E 
 
Self-Stigma of Seeking Help Scale  
 
Instructions: People at times find that they face problems for which they would consider seeking 
professional help. This can bring up reactions about what seeking help would mean. Please use 
the 5-point scale to rate the degree to which each item describes how you might react if you 
decided you needed to seek out professional help.  
 
 Strongly 
Disagree 
 
Disagree 
 
Neutral 
 
Agree 
Strongly 
Agree 
1. I would feel inadequate if I went to a 
therapist for psychological help.  1 2 3 4 5 
2. My self-confidence would NOT be 
threatened if I sought professional help.  1 2 3 4 5 
3. Seeking psychological help would make me 
feel less intelligent.  1 2 3 4 5 
4. My self-esteem would increase if I talked to 
a therapist.  1 2 3 4 5 
5. My view of myself would not change just 
because I made the choice to see a therapist.  1 2 3 4 5 
6. It would make me feel inferior to ask a 
therapist for help.  1 2 3 4 5 
7. I would feel okay about myself if I made the 
choice to seek professional help.  1 2 3 4 5 
8. If I went to a therapist, I would be less 
satisfied with myself.  1 2 3 4 5 
9. My self-confidence would remain the same 
if I sought professional help for a problem I 
could not solve.  
1 2 3 4 5 
10. I would feel worse about myself if I could 
not solve my own problems.  1 2 3 4 5 
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Appendix F 
Demographics  
1. What is your age? 
2. What is your gender? 
 Male  Female  
3. What is your ethnicity?  
 4. What is your marital status? 
 Single Married Divorced 
 Separated   Widow (er)  
5. What is your highest level of obtained education? 
 Some High School High School Diploma or Equivalent Some College 
 Associates Degree Bachelors Degree Masters Degree Doctorate  
6. What is the highest level of obtained education for your mother? 
Unsure Some High School Diploma or equivalent 
 Some College Associates Degree Bachelors Masters Doctorate  
7a. Are you currently in ROTC?  
Yes   No 
 
 7b. If so, how long have you been in the ROTC?  
 
 7c. After you graduate college, do you plan on joining the military?  
 
 7d. If so, which branch of service will you join? 
8a. Are you currently or have you ever been in the US military? 
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8b. If so, please indicate your branch of military service:  
 Marine Corps Air Force ARMY Navy Coast Guard 
8c. Please indicate how long you were in the military:  
8d. What was your highest obtained military rank?  
 
8e. Are you currently active duty, national guard, reserve, or Veteran? 
 
9a. Have you ever served a combat deployment? 
 
9b. Number of combat deployments: 
 
9c. Approximate time in months of all deployments combined:  
 
10. How would you describe the childhood environment that you feel has influenced you 
the most today?  
 
|--------------|-------------|---------------|--------------|-------------|--------------|-------------| 
Extremely     Very          Somewhat           Slightly         Slightly        Somewhat          Very           Extremely    
Rural            Rural         Rural                Rural             Urban          Urban                Urban         Urban  
 
11. How would you describe the environment were you currently reside?  
 
|--------------|-------------|---------------|--------------|-------------|--------------|-------------| 
Extremely     Very          Somewhat           Slightly         Slightly        Somewhat          Very           Extremely    
Rural             Rural         Rural                Rural             Urban          Urban               Urban         Urban  
